Quick Summary
The Serum Institute TB Vaccine Partnership 2026 marks a significant step in global tuberculosis prevention. The Serum Institute of India will manufacture the investigational M72/AS01E TB vaccine under a partnership with the Gates Medical Research Institute (Gates MRI), subject to successful Phase 3 clinical trials and regulatory approval. If approved, it could become the first new TB vaccine introduced in more than 100 years.
Serum Institute TB Vaccine Partnership 2026 Announced
The Serum Institute TB Vaccine Partnership 2026 has been announced as a strategic collaboration between the Serum Institute of India (SII) and the Gates Medical Research Institute (Gates MRI) to manufacture the investigational tuberculosis vaccine M72/AS01E.
The vaccine is currently undergoing Phase 3 clinical trials and has not yet received regulatory approval. If the ongoing trials confirm its safety and effectiveness, it may become the first new tuberculosis vaccine in over a century, offering hope for millions of people living in countries with a high TB burden.
Overview
| Particular | Details |
|---|---|
| Vaccine Candidate | M72/AS01E |
| Manufacturer | Serum Institute of India (SII) |
| Partner Organization | Gates Medical Research Institute (Gates MRI) |
| Clinical Trial Stage | Phase 3 |
| Manufacturing Status | Technology Transfer Initiated |
| Planned Investment | More than US$100 Million |
| Adjuvant Supplier | GSK |
| Target Disease | Tuberculosis (TB) |
What is M72/AS01E?
M72/AS01E is an investigational vaccine designed to help prevent active pulmonary tuberculosis (TB) in adolescents and adults.
Key Highlights
- Experimental TB vaccine
- Developed over nearly two decades
- Currently in Phase 3 clinical trials
- Intended for adolescents and adults
- Aims to reduce active pulmonary TB
Serum Institute’s Role
Under the partnership agreement:
- Serum Institute of India will manufacture the M72 antigen.
- Gates MRI will provide technology transfer and manufacturing expertise.
- Serum Institute plans to invest over US$100 million to expand manufacturing capacity.
- Commercial production will begin only after successful clinical trials and regulatory approval.
GSK’s Contribution
The vaccine candidate was originally developed by GSK.
Under the current collaboration:
- GSK continues supplying the AS01E adjuvant.
- Gates MRI sponsors the ongoing Phase 3 clinical trial.
- The Gates Foundation and Wellcome are funding the late-stage clinical development.
Why This Vaccine Matters
Tuberculosis remains one of the world’s leading infectious diseases.
According to the World Health Organization (WHO):
| Global TB Statistics | Data |
|---|---|
| Estimated TB Cases (2024) | Around 11 Million |
| Estimated Deaths | Approximately 1.23 Million |
| High-Burden Countries | India, Indonesia, Pakistan, China, Nigeria, Philippines |
These figures highlight the urgent need for more effective TB prevention strategies.
Potential Global Impact
The World Health Organization (WHO) estimates that a vaccine with efficacy similar to M72/AS01E could significantly reduce the global TB burden.
| Expected Impact | Estimated Benefit |
|---|---|
| New TB Cases Prevented | 76 Million |
| Lives Saved | 8.5 Million |
| Healthcare & Household Savings | US$41.5 Billion (over 25 years) |
These projections demonstrate the vaccine’s potential to transform tuberculosis prevention worldwide, especially in low- and middle-income countries.
Current Status of the Vaccine
The M72/AS01E vaccine is currently being evaluated in a Phase 3 randomized clinical trial that began in March 2024.
Trial Highlights
- Approximately 20,000 participants
- 54 clinical trial sites
- Countries involved:
- South Africa
- Kenya
- Malawi
- Zambia
- Indonesia
If the trial successfully demonstrates safety and efficacy, the vaccine will proceed toward regulatory approval and commercial manufacturing.
Why This Partnership is Important
This collaboration aims to ensure that manufacturing infrastructure is ready before regulatory approval.
Expected Benefits
- Faster vaccine availability after approval
- Large-scale manufacturing capacity
- Affordable global vaccine supply
- Better access for high TB burden countries
- Reduced delays in vaccine distribution
Why Should Pharmacy Students and Healthcare Professionals Know About This?
Although this is not a recruitment notification, the partnership is highly relevant for B.Pharm, M.Pharm, Pharm.D students, researchers, and healthcare professionals.
Key Learning Opportunities
- Understanding vaccine development and manufacturing
- Exposure to global clinical research
- Insights into biotechnology and pharmaceutical production
- Knowledge of public health innovation
- Awareness of international collaborations in vaccine development
Important Milestones
| Event | Status |
|---|---|
| Technology Transfer | Initiated |
| Phase 3 Trial | Ongoing |
| Manufacturing Preparation | In Progress |
| Regulatory Approval | Pending |
| Commercial Manufacturing | Subject to Approval |
Important Links
| Description | Status |
|---|---|
| Official Serum Institute Website | Available |
| Gates Medical Research Institute | Available |
| WHO Tuberculosis Information | Available |
Conclusion
The Serum Institute TB Vaccine Partnership 2026 represents a major milestone in global efforts to combat tuberculosis. With M72/AS01E currently in Phase 3 clinical trials, the collaboration between the Serum Institute of India and Gates Medical Research Institute aims to ensure rapid manufacturing once regulatory approval is obtained. If successful, the vaccine could become the first new TB vaccine introduced in more than 100 years, potentially preventing millions of cases and saving millions of lives worldwide.
Frequently Asked Questions (FAQs)
Q1. What is M72/AS01E?
M72/AS01E is an investigational tuberculosis vaccine currently undergoing Phase 3 clinical trials.
Q2. Who will manufacture the vaccine?
The Serum Institute of India will manufacture the vaccine under a partnership with the Gates Medical Research Institute, subject to successful clinical trials and regulatory approval.
Q3. Is the vaccine approved?
No. The vaccine is currently in Phase 3 clinical trials and has not yet received regulatory approval.
Q4. How much is Serum Institute investing?
Serum Institute plans to invest more than US$100 million to expand manufacturing capacity.
Q5. Who developed the vaccine?
The vaccine was originally developed by GSK, which later licensed it to Gates Medical Research Institute in 2020.
Q6. Which organizations are funding the Phase 3 trial?
The Gates Foundation and Wellcome are funding the late-stage clinical development.
Q7. Which countries are participating in the Phase 3 trial?
The trial is being conducted in:
- South Africa
- Kenya
- Malawi
- Zambia
- Indonesia
Q8. Why is this vaccine important?
If approved, M72/AS01E could become the first new tuberculosis vaccine in over 100 years, helping prevent millions of TB cases and reducing deaths worldwide.
Recommended Products
